## 1 High-throughput immunoassays for SARS-CoV-2 – considerable differences in

### 2 performance when comparing three methods

- 3 Oskar Ekelund, MD<sup>1,2</sup>, Kim Ekblom, MD, PhD<sup>3,4</sup>, Sofia Somajo, MSc, PhD<sup>2</sup>, Johanna
- 4 Pattison-Granberg PhD<sup>3</sup>, Karl Olsson, BSc<sup>2</sup>, and Annika Petersson, MSc, PhD<sup>3</sup>
- <sup>1</sup>Department of Clinical Microbiology, Växjö Central Hospital, Växjö, Sweden; <sup>2</sup>Department
- 6 of Clinical Microbiology, Blekinge County Hospital, Karlskrona, Sweden; <sup>3</sup>Department of
- 7 Clinical Chemistry and Transfusion Medicine, Växjö Central Hospital, Växjö, Sweden;
- <sup>4</sup>Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden
- 9

10 11 12 13 14 15 16 17 18	Corresponding author:	Annika Petersson Department of Clinical Chemistry and Transfusion Medicine Centrallasarettet Växjö SE-35185 Växjö Sweden phone +46 (0)470 58 7978 cell phone +46 (0) 767 259609 e-mail <u>annika.petersson@kronoberg.se</u>
20	Running head: Serology	methods for SARS-CoV-2
21	Author ORCID ID:	Oskar Ekelund 0000-0001-6621-0244
22		Kim Ekblom 0000-0003-2844-1310
23		Sofia Somajo 0000-0003-0433-8079
24		Johanna Pattison-Granberg 0000-0002-3979-996X
25		Karl Olsson -
26		Annika Petersson 0000-0002-4582-3567

# 28 Abstract

29	Background: The recently launched high-throughput assays for the detection of antibodies
30	against SARS-CoV-2 may change the managing strategies for the COVID-19 pandemic. This
31	study aimed at investigating the performance of three high-throughput assays and one rapid
32	lateral flow test relative to the recommended criteria defined by regulatory authorities.
33	Methods: A total of 133 samples, including 100 pre-pandemic samples, 20 samples from
34	SARS-CoV-2 RT-PCR positive individuals, and 13 potentially cross-reactive samples were
35	analysed with SARS-CoV-2 IgG (Abbott), Elecsys Anti-SARS-CoV-2 (Roche), LIAISON
36	SARS-CoV-2 S1/S2 IgG (DiaSorin) and 2019-nCOV IgG/IgM Rapid Test (Dynamiker
37	Biotechnology Co).
38	Results: All assays performed with a high level of specificity; however, only Abbott reached
39	100% (95% CI 96.3-100). The pre-pandemic samples analysed with Roche, DiaSorin and
40	Dynamiker Biotechnology resulted in two to three false-positive results per method
41	(specificity 96.9-98.0%). Sensitivity differed more between the assays, Roche exhibiting the
42	highest sensitivity (100%, CI 83.9-100). The corresponding figures for Abbott, DiaSorin and
43	Dynamiker Biotechnology were 85.0%, 77.8% and 75.0%, respectively.
44	Conclusions: The results of the evaluated SARS-CoV-2 assays vary considerably as well as
45	their ability to fulfil the performance criteria proposed by regulatory authorities. Introduction
46	into clinical use in low-prevalent settings, should therefore, be made with caution.
47	

48 Keywords: COVID-19, SARS-CoV-2, serology, immunology, antibodies

# 50 Introduction

51	Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, Hubei province, China,
52	in December 2019 [1]. The virus causing this disease has since been designated SARS-CoV-2
53	[2]. The clinical manifestations of COVID-19 range from mild or no respiratory symptoms to
54	severe viral pneumonia with a need of intensive care and ventilator support. Due to the rapid
55	dissemination of the infection, the outbreak was declared a pandemic by the World Health
56	Organization (WHO) on 11 <sup>th</sup> March 2020 [3].
57	RT-PCR detection of SARS-CoV-2 in samples primarily obtained from
58	nasopharyngeal and/or pharyngeal swabs is considered gold standard for laboratory
59	confirmation of COVID-19 in patients. However, the presence of viral nucleic acids is
60	transient, and results are dependent on the time of sampling.
61	Detection of antibodies against the SARS-CoV-2 virus could possibly be used to
62	distinguish patients recovered from COVID-19, and several rapid tests based on
63	immunochromatographic techniques have been developed. These point-of-care tests usually
64	deliver results within 15-30 minutes, however the nature of the tests makes large-scale testing
65	inefficient.
66	To achieve high-throughput detection of anti-SARS-CoV-2 antibodies in plasma
67	or serum, several manufacturers have developed immunoassays based on recognition of
68	recombinant antigens. Some tests claim to detect IgM or IgG, while others also identify IgA
69	or a mixture of different classes of antibodies. Differences in test design, including choice of
70	antigen, are likely to affect the sensitivity and specificity of the tests [4]. In this study, the
71	performance of three commercially available high-throughput automated SARS-CoV-2
72	antibody assays, and one rapid immunochromatographic test, was investigated and compared
73	to recommended criteria set by regulatory authorities.
74	

# 75 Materials and Methods

76 Assays

77	Four commercially available CE marked immunoassays, and their corresponding platforms
78	were used: 1) Abbott SARS-CoV-2 IgG on the ARCHITECT i2000 (Abbott, Illinois, USA);
79	2) Elecsys Anti-SARS-CoV-2 on the Cobas 8000 e801 (Roche Diagnostic Scandinavia AB,
80	Solna, Sweden); 3) LIAISON SARS-CoV-2 S1/S2 IgG on the LIAISON XL (DiaSorin,
81	Saluggia, Italy); and 4) the lateral flow test 2019-nCOV IgG/IgM Rapid Test (Dynamiker
82	Biotechnology Co., Tianjin, China).
83	The Abbott SARS-CoV-2 IgG reagent is based on the recognition of IgG
84	antibodies binding to recombinant SARS-CoV-2 nucleoprotein in a chemiluminescent
85	microparticle immunoassay (CMIA). Results are obtained after 29 minutes, and are reported
86	as an index with a cut-off to distinguish between negative and positive results.
87	The Elecsys Anti-SARS-CoV-2 assay is based on recombinantly produced
88	SARS-CoV-2 nucleocapsid (N) protein and detects antibodies (including IgG). The duration
89	of the analysis is approximately 18 minutes, with results presented as a cut-off index as well
90	as reactive or non-reactive.
91	The LIAISON SARS-CoV-2 S1/S2 detects IgG antibodies recognising the spike
92	glycoprotein of the coronavirus. As for the previous assays, the antigen is composed of
93	recombinant protein expressed in human cell lines. The analysis takes 35 minutes, and the
94	results are expressed as IgG antibody concentrations in arbitrary units (AU/mL) graded
95	negative, equivocal, or positive.
96	The manually performed 2019-nCOV IgG/IgM Rapid Test recognises and
97	differentiates IgG from IgM antibodies; however, information on antigen source is scarce.
98	The test result could be obtained after approximately 10 minutes as visual bands across the
99	assay paper strip, any positive result, either for IgG, IgM, or both, was considered positive.

100	Despite the short reaction time, as compared with the automatic tests, high-throughput
101	analysis of a large number of samples using the manual test procedure is implausible.
102	All automated systems are part of the routine operations in our laboratories and
103	were as such subjected to accepted quality assurance procedures. All tests (including
104	calibration and controls) were performed according to manufacturers' instructions, using
105	serum samples.
106	
107	Sample collections
108	All samples in the study originated from an existing sample collection at the Microbiology
109	department obtained after consent to deposit, store, and use for research and development.
110	Samples were fully anonymised prior to inclusion, and results could hence not be linked to
111	individuals. As a consequence, the study did not require approval from an ethics committee,
112	according to the guidelines of the Swedish Ethical Review Agency. All serum samples were
113	stored at -20°C until analysis.
114	The specificity of each assay was evaluated using 100 pre-pandemic (2018)
115	samples. To challenge the assays, 13 additional serum samples with possible interferences
116	(antinuclear antibodies (n=2); rheumatoid factor (n=2); anti-cytomegalovirus IgM (n=2); anti-
117	Epstein-Barr virus IgM (n=2) and samples from pregnant donors (n=5)) were analysed.
118	Assay sensitivities were evaluated using 20 outpatient serum samples from 16
119	individuals that prior to serum sampling had tested RT-PCR positive for SARS-CoV-2 from
120	nasopharyngeal and/or pharyngeal swabs. RT-PCR had been performed using primers and
121	probes targeting either the envelope (E) and the polymerase (RdRP) genes of SARS-CoV-2 as
122	described by Corman [5], or the nucleocapsid gene (N) of the virus (Abbott RealTime SARS-
123	CoV-2 Assay, Abbott Molecular Inc., Illinois, USA). The interval between onset of COVID-

# 125 Calculations

126	Overall per cent agreement, sensitivity (per cent positive agreement), and specifi	icity (per cent					
127	negative agreement) were calculated based on a contingency table according to EP12-A2 [6],						
128	using Microsoft Excel 2019 (Microsoft Corp. Redmond, WA, USA). The between-test						
129	agreement was evaluated using Cohen's kappa calculated with IBM SPSS Statis	tics for					
130	Windows, Version 26.0 (IBM Corp., Armonk, NY, USA). For each assay, the pe	ositive					
131	likelihood ratio (LR+) and positive predictive value (PPV) at different prevalence	e (P)					
132	scenarios were calculated according to equation 1 and 2, respectively.						
133	LR + = sensitivity/(1 - specificity)	(Eq. 1)					
134	$PPV = (sensitivity \ x \ P) / ((sensitivity \ x \ P) + (1 - specificity) \ x \ (1 - P))$	(Eq. 2)					
135	Further data analysis, including descriptive statistics, was performed using Grap	hPad Prism,					
136	version 7.04 for Windows (GraphPad Software, La Jolla California USA,						
137	www.graphpad.com).						
138							
139	Clinical Performance Requirements						
140	The performance of each assay was compared with published guidelines from th	ree regulatory					
141	authorities: the Public Health Agency of Sweden (PHAS); Haute Autorité de Santé, France						
142	(HAS); and Centres for Disease Control and Prevention, USA (CDC) [7-9]. Their						
143	recommended performance criteria are summarized in Table 1.						

**Results** 

- 145 Of the 100 pre-pandemic samples, nine tested false positive, two with Roche, five with
- 146 DiaSorin (including two equivocal results) and two with Dynamiker Biotechnology (figure 1).
- 147 The negative sample collection resulted in median values of 0.09 COI (0.08-3.16), 0.04 S/CO

148 (0.01-0.6) and 5.7 AU/mL (1.9-32.6) for Roche, Abbott and DiaSorin, respectively. The panel 149 consisting of 13 potentially cross-reactive pre-pandemic samples mainly gave negative 150 results. However, for Dynamiker Biotechnology, one sample with rheumatoid factor IgM was 151 positive for both SARS-CoV-2 IgM and IgG. Also, one sample obtained during pregnancy 152 showed an equivocal result on the DiaSorin assay. In contrast, all these samples were negative 153 on the Abbott and Roche assays. 154 Three RT-PCR positive samples gave a weak positive result with Roche, close 155 to the cut-off (1.01 to 1.26, cut-off  $\geq$ 1.0) (Figure 1). These samples were reported as negative 156 by DiaSorin, Dynamiker Biotechnology, and Abbott. However, for these samples, the Abbott

values clearly differed from the rest of the Abbott negative samples by being close to the cutoff (0.81-1.06, cut-off  $\geq$  1.4).

159The overall agreement was 97.5% for Abbott, 98.3% for Roche, 94.0% for160DiaSorin, and 94.2% for Dynamiker Biotechnology. The pairwise inter-assay agreement161(Cohen's kappa) was as follows: Roche and Abbott 0.847 (95% CI, 0.718 to 0.976); Roche162and Diasorin 0.654 (95% CI, 0.474 to 0.830); Roche and Dynamiker Biotechnology 0.794163(95% CI, 0.647 to 0.941); Abbott and DiaSorin 0.777 (95% CI, 0.618 to 0.936); Abbott and164Dynamiker Biotechnology 0.804 (95% CI, 0.653 to 0.817); and DiaSorin and Dynamiker165Biotechnology 0.724 (95% CI, 0.533 to 0.895).

The calculated sensitivity and specificity for each assay is presented in Table 2, together with the corresponding data extracted from each manufacturer's test kit insert. In the present study Abbott exhibited the highest specificity and Roche the highest sensitivity, both being 100%. Two RT-PCR positive samples and two samples from the negative collection were excluded from the DiaSorin sample collection due to equivocal results. The positive 171 likelihood ratios (LR+) were  $\infty$ , 50.0, 25.1 and 37.5 for Abbott, Roche, DiaSorin and

172 Dynamiker Biotechnology, respectively.

173	Benchmarking the sensitivity and specificity data from the current study against
174	published guidelines showed that the Abbott assay met the specificity criteria set by all three
175	regulatory bodies. The specificities of Roche and Dynamiker Biotechnology were both in
176	accordance with the HAS guidelines, while DiaSorin, in contrast, failed to reach any of the
177	specificity criteria. Neither of the assays from Abbott, DiaSorin and Dynamiker
178	Biotechnology exhibited a sufficient sensitivity to meet the criteria set by PHAS and HAS. In
179	contrast, Roche performed excellent in this regard, with a sensitivity of 100%.
180	Assay performance recommendations from PHAS are based on a target PPV of
181	> 90%. To demonstrate the seroprevalence required to reach a PPV of $>$ 90%, the PPV based
182	on sensitivity and specificity data from the present study as well as from the manufacturers,

183 was calculated (Figure 2).

### 184 Discussion

185 As the pandemic progresses, it will likely become increasingly important not only to establish 186 ongoing COVID-19 but also to confirm past infection of SARS-CoV-2. On a community level, this could be used for assessing the progress of the pandemic and for guiding public 187 188 health and control policies [10]. On an individual level, a reliable method for proving past 189 COVID-19 could potentially be important for allowing employees to remain at work despite 190 mild respiratory symptoms. It could even serve as a basis for a proposed "immunity passport" 191 [11, 12]. Although the degree of immunity to SARS-CoV-2 is disputed, it is plausible that 192 individuals undergoing COVID-19 will gain partial or temporary protection against new 193 episodes [13]. Serology tests might also be used to identify donors of convalescent plasma, which has been proposed for the treatment of seriously ill COVID-19 patients [14]. 194

However, the rapidly emerging pandemic limits the possibility of state-of-the-art validations according to the EP-12 A2 [6], and there is no international consensus on clinical performance requirements for COVID-19 assays. Neither is there an agreed gold standard method for antibody testing [15]. Using the performance criteria proposed by PHAS, HAS and CDC [7-9], only Abbott managed to reach the specificity recommended by all three authorities while Roche alone fulfilled the sensitivity criteria (PHAS, HAS).

201 The clinical performance of a qualitative diagnostic test is, with few exceptions, 202 heavily dependent on the prevalence. Both PHAS and CDC accordingly link their respective 203 specificity criteria for SARS-CoV-2 antibody testing to seroprevalence levels. PHAS 204 recommends that a PPV > 90% shall be pursued, regardless of seroprevalence. Based on our 205 results prevalences of approximately 15%, 20% and 25% would be necessary to reach this 206 goal for Roche, Dynamiker Biotechnology and DiaSorin, respectively (Figure 2). In contrast, 207 Abbott would in this regard perform well at any given seroprevalence, owing to its specificity 208 of 100%.

Due to the limited sample size of the study, our results need to be interpreted with caution. Nevertheless, a recent study based on 65 RT-PCR positive and 1154 pre-COVID-19 samples [16] reported similar assay performances, except for the sensitivity of Roche being higher in our study. In contrast, evaluating four different assays using the same outpatient sample collection strengthens this study. Moreover, an aspect not investigated in this study is that assay performance could potentially vary with sample type (serum, plasma, whole blood).

Judging by the results from this study, introducing broad antibody testing for COVID-19 will be cumbersome in a low-prevalence setting. In order to reach the proposed performance criteria, two-tier testing will have to be considered. Alternatively, a high degree of specificity (and thus a high positive predictive value) could be prioritised using modified

220	cut-off values. Our results suggest that this could be conceivable for the Abbott and Roche
221	assays, while the more narrowly distributed results for DiaSorin would make it difficult to
222	find such a specific cut-off with a reasonably preserved degree of sensitivity (Figure 1).
223	Considering the novelty of the disease, and hence the expedited development of
224	new assays, possible sources of systematic errors (e.g. cross-reacting antibodies against other
225	Coronaviridae) need to be carefully considered. In this study, all eleven false-positive
226	samples originated from unique donors, none of the samples being positive in more than one
227	assay. Further investigation of possible reasons for the false-positive results is, however,
228	beyond the scope of this evaluation.
229	We conclude that the SARS-CoV-2 assays only partly fulfil the performance
230	criteria proposed by regulatory authorities. Introduction into clinical use in low-prevalent
231	settings, must therefore, be made with careful consideration and well-informed stakeholders.
232	
233	Acknowledgements
234	The expert technical assistance of Ola Forsell and Susanna Bergqvist at the Department of
235	Clinical Chemistry and Transfusion Medicine, Växjö Central Hospital, and of Sanna
236	Hjalmarsson, Christina Bojesson and Eline Boesen at the Department of Clinical
237	Microbiology, Region Kronoberg, is greatly appreciated.
238	
239	Declaration of interest statement: The authors declare that they have no conflicts of interest
240	relevant to the manuscript submitted to Infectious Diseases. There is no funding to report.
241	

#### 242 **References**

- 243 [1] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu,
- 244 F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G.F. Gao, W. Tan, I. China Novel Coronavirus, T.
- 245 Research, A Novel Coronavirus from Patients with Pneumonia in China, 2019, N Engl J Med 382(8)
- 246 (2020) 727-733.
- 247 [2] A.E. Gorbalenya, S.C. Baker, R.S. Baric, R.J. De Groot, C. Drosten, A.A. Gulyaeva, B.L.
- 248 Haagmans, C. Lauber, A.M. Leontovich, B.W. Neuman, D. Penzar, S. Perlman, L.L.M. Poon, D.
- 249 Samborskiy, I.A. Sidorov, I. Sola, J. Ziebuhr, Severe acute respiratory syndrome-related coronavirus:
- 250 The species and its viruses a statement of the Coronavirus Study Group, Cold Spring Harbor
- Laboratory, 2020.
- [3] WHO, Virtual press conference on COVID-19–11 March 2020.
- 253 <<u>https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-</u>
- 254 <u>coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3\_2</u>>, 2020 (accessed 6th
- 255 May.2020).
- 256 [4] Z. Zainol Rashid, S.N. Othman, M.N. Abdul Samat, U.K. Ali, K.K. Wong, Diagnostic
- 257 performance of COVID-19 serology assays, Malays J Pathol 42(1) (2020) 13-21.
- 258 [5] V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, T. Bleicker, S. Brunink,
- 259 J. Schneider, M.L. Schmidt, D.G. Mulders, B.L. Haagmans, B. van der Veer, S. van den Brink, L.
- 260 Wijsman, G. Goderski, J.L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, M.P.
- 261 Koopmans, C. Drosten, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,
- 262 Euro Surveill 25(3) (2020).
- 263 [6] P.E. Garrett, F.D. Lasky, K.L. Meier, L.W. Clark, Clinical and Laboratory Standards Institute.,
- 264 User protocol for evaluation of qualitative test performance : approved guideline, 2nd ed., Clinical and
- Laboratory Standards Institute, Wayne, Pa., 2008.
- 266 [7] Folkhälsomyndigheten (Public Health Agency of Sweden), Vägledning för antikroppspåvisning.
- 267 <<u>https://www.folkhalsomyndigheten.se/contentassets/2c3d8e40926e4bcc942aa640922bb758/vagledni</u>
- 268 <u>ng-antikroppspavisning.pdf</u>>, 2020 (accessed 3 Jul.2020).

- 269 [8] Haute Authorité de Santé, Specifications setting out the performance assessment methods
- 270 applicable to serological tests detecting anti-SARS-CoV-2 antibodies. <<u>https://www.has-</u>
- 271 sante.fr/upload/docs/application/pdf/2020-05/has\_serological\_tests\_covid19\_specifications.pdf>, 2020
- 272 (accessed Jul 31.2020).
- 273 [9] Centers for Disease Control and Prevention, Interim Guidelines for COVID-19 Antibody Testing;
- 274 Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings.
- 275 <<u>https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html</u>>, 2020
- 276 (accessed Jul 31.2020).
- [10] S.E.F. Yong, D.E. Anderson, W.E. Wei, J. Pang, W.N. Chia, C.W. Tan, Y.L. Teoh, P.
- 278 Rajendram, M. Toh, C. Poh, V.T.J. Koh, J. Lum, N.M. Suhaimi, P.Y. Chia, M.I. Chen, S. Vasoo, B.
- 279 Ong, Y.S. Leo, L. Wang, V.J.M. Lee, Connecting clusters of COVID-19: an epidemiological and
- 280 serological investigation, Lancet Infect Dis (2020).
- [11] A.L. Phelan, COVID-19 immunity passports and vaccination certificates: scientific, equitable,
- and legal challenges, Lancet (2020).
- [12] N.J. Beeching, T.E. Fletcher, M.B.J. Beadsworth, Covid-19: testing times, BMJ 369 (2020)
- 284 m1403.
- 285 [13] L. Bao, W. Deng, H. Gao, C. Xiao, J. Liu, J. Xue, Q. Lv, J. Liu, P. Yu, Y. Xu, F. Qi, Y. Qu, F. Li,
- 286 Z. Xiang, H. Yu, S. Gong, M. Liu, G. Wang, S. Wang, Z. Song, W. Zhao, Y. Han, L. Zhao, X. Liu, Q.
- 287 Wei, C. Qin, Reinfection could not occur in SARS-CoV-2 infected rhesus macaques, bioRxiv (2020)
- 288 2020.03.13.990226.
- [14] R. Rubin, Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19,
- 290 JAMA (2020).
- [15] European Commission, Guidelines on COVID-19 in vitro diagnostic tests and their performance
- 292 (2020/C 122 I/01) <<u>https://eur-lex.europa.eu/legal-</u>
- 293 content/EN/TXT/PDF/?uri=OJ:C:2020:122I:FULL&from=SV>, 2020 (accessed Aug. 4.2020).
- 294 [16] T. Perkmann, N. Perkmann-Nagele, M.-K. Breyer, R. Breyer-Kohansal, O.C. Burghuber, S. Hartl,
- 295 D. Aletaha, D. Sieghart, P. Quehenberger, R. Marculescu, P. Mucher, R. Strassl, O.F. Wagner, C.J.

- 296 Binder, H. Haslacher, Side by side comparison of three fully automated SARS-CoV-2 antibody assays
- 297 with a focus on specificity, medRxiv (2020) 2020.06.04.20117911.

<b>Regulatory Authority</b>	Sensitivity (%)	Specificity (%)	Additional comment
Public Health Agency of Sweden	90.0	99.5	Recommendations based on a seroprevalence of $5\%$ rendering a target PPV of $> 90\%$
Haute Autorité de Santé, France	95.0	98.0	
Centers for Disease Control and Prevention, USA	-	99.5	For populations with seroprevalence of $\geq 5\%$

Table 1. Summary of recommended criteria for SARS-CoV-2 serology assays issued by authorities in three different countries.

Table 2. Sensitivity and specificity from this study, and according to the manufacturers' data. The results are compared to manufacturers' data from samples collected >14 days (Abbott, Roche) and >15 days (DiaSorin) post PCR confirmation. No information about time of sampling was

309 available for Dynamiker Biotechnology.

	Study Data			Manufacturer's Data*				
	n	Sensitivity % (95% CI)	n	Specificity % (95% CI)	n	Sensitivity (95% CI)	n	Specificity (95% CI)
Abbott	20	85.0 (64.0-94.8)	100	100 (96.3-100)	73	100 (95.1-100)	997	99.6 (99.0-99.9)
Roche	20	100 (83.9-100)	100	98.0 (93.0-99.5)	185	99.5 (97.0-100)	6305	99.8 (99.7-99.9)
DiaSorin	18	77.8 (54.8-91.0)	98	96.9 (91.4-99.0)	39	97.4 (86.8-99.5)	90	98.9 (94.0-99.8)
Dynamiker	20	75.0 (53.1-88.8)	100	98.0 (93.0-99.5)	162	93.2 (not reported)	300	95.3 (not reported)

310 \* Data retrieved from following versions of product kit inserts: Abbott 06R86 G90418R01, April 2020; Roche V3, 2020-06; DiaSorin 200/007-797, 03, 2020-04; Dynamiker

311 Biotechnology DNK-1419-1.

312



Figure 1.





#### 318 Figure captions

- 319 Figure 1. Differences in distribution patterns between Abbott, Roche and DiaSorin immunoassays for
- 320 detection of SARS-CoV-2 antibodies. Measured values from serology testing of 20 positive (SARS-
- 321 CoV-2 PCR confirmed) and 100 negative (pre-pandemic 2018) samples. Dotted lines represent cut-off
- 322 values of A) Abbott: positive result index  $\geq$  1.4 S/CO, B) Roche: positive cut-off index (COI)  $\geq$  1.0,
- and C) DiaSorin: positive cut-off  $\geq$  15 AU/mL and equivocal 12-15 AU/mL. In C negative samples
- 324 with signals below detection limit (3.8 AU/ml) were plotted as 1.9 AU/mL.

325

- Figure 2. Estimated PPV for the depicted assays, calculated at seroprevalences of 1%, 5%, 10%, 15%,
- 327 20%, 25% and 50%. Calculations were based on sensitivity, specificity and their respective 95% CI
- 328 limits from the current investigation (solid lines = mean values; grey areas = 95% CI). Dashed lines
- 329 represent mean sensitivity and specificity data from the manufacturers' kit inserts. Dotted horizontal
- 330 lines refer to 90% PPV.
- 331

332

333

334335

- - - -